MyOme

-38%

est. 2Y upside i

HealthcareSeries B

MyOme is a clinical whole genome analysis platform company helping families understand their risk for inherited diseases.

Rank

#3081

Sector

Biotechnology

Est. Liquidity

~3Y

Data Quality

Data: Low

Given a 2-year horizon, expected equity upside is -38% with high risk.

Last updated: July 19, 2026

Bull (30%)+4%

MyOme sustains 10x revenue multiple driven by IPO or category leadership, exit value ~$137M, yielding 4% upside from $132M entry.

Base (50%)-38%

Multiple compresses to 6x as growth decelerates; revenue ~$13.7M yields $82M exit, a 38% loss given entry valuation at 16.9x.

Bear (20%)-100%

Multiple falls to 3x, exit value $41M below $100M preference stack, rendering common stock worthless.

Est. time to liquidity~3.0 years

Preference Stack Risk

severe

Funding Intensity

7576%

Total preferred stock liquidation preference of $100M represents 76% of the $132M entry valuation, significantly diluting common stock in downside.

Dilution Risk

moderate

Recent $63.5M Series B provides ~2 years runway, but unprofitability and high capex may necessitate additional financing.

Secondary Liquidity

none

No secondary transactions reported; liquidity likely restricted until exit.

Other — 6 roles

Bioinformatics Analyst - Lead · San Francisco, California, United States
Clinical Evidence Director · Menlo Park, California, United States; Menlo Park, California, United States
Group Lead, Assay Development - Molecular Biology & Bioinformatics (NGS) · Menlo Park, California, United States
+3 more →

Last updated: February 22, 2026

Questions to Ask at the Interview

Strategic questions based on MyOme's data — designed to show you've done your homework.

1
“How does MyOme's AI-integrated risk model differ from competitors' approaches and what is its clinical validation status?”
2
“What is the unit economics and path to profitability given high capital intensity?”
3
“How does the current valuation reflect the Series B step-up and what is the timeline for next fundraising?”

Our model estimates -38% upside. What do you think?

Anonymous. Do not share material non-public information.

Comments are reviewed before they appear publicly.

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.